Mayo Clinic Review: Can CBD Help Treat Heart Disease?

CBD shows promising anti-inflammatory and cardioprotective properties in preclinical studies, but clinical evidence for cardiovascular applications remains limited.

Abdalla, Hesham M et al.·Mayo Clinic proceedings·2026·Preliminary EvidenceNarrative Review
RTHC-08059Narrative ReviewPreliminary Evidence2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

CBD demonstrates potential anti-inflammatory, antioxidant, and vasodilatory properties relevant to pericarditis, ischemic heart disease, heart failure, and cardiac arrhythmias, with preliminary trials showing promise for recurrent pericarditis.

Key Numbers

Review covered evidence on CBD's role across multiple cardiovascular conditions including ischemia-reperfusion injury, myocardial fibrosis, and cardiac arrhythmias.

How They Did This

Narrative review from Mayo Clinic researchers integrating preclinical and emerging clinical evidence on CBD in cardiovascular disease management.

Why This Research Matters

Heart disease remains the leading cause of death globally, and CBD's unique anti-inflammatory profile — without immunosuppressive effects — could fill a gap in treating inflammatory cardiac conditions.

The Bigger Picture

If clinical trials confirm preclinical findings, CBD could become a nonimmunosuppressive therapy option for inflammatory heart conditions — a category with few current alternatives.

What This Study Doesn't Tell Us

Most evidence comes from preclinical models; limited human clinical trials, dosing inconsistencies, and regulatory challenges hinder translation to clinical practice.

Questions This Raises

  • ?What are the optimal CBD doses for cardiovascular benefit?
  • ?How do CBD drug interactions affect cardiac medications?
  • ?Can large-scale trials validate the preclinical cardioprotective signals?

Trust & Context

Key Stat:
Evidence Grade:
Comprehensive narrative review from a leading medical institution, but limited by the scarcity of human clinical trials and dosing standardization.
Study Age:
Published in 2026 in Mayo Clinic Proceedings, reflecting cutting-edge cardiovascular cannabinoid research.
Original Title:
Cannabidiol in Cardiovascular Disease: A Review of Current Evidence and Future Directions.
Published In:
Mayo Clinic proceedings, 101(2), 297-309 (2026)
Database ID:
RTHC-08059

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

Can CBD treat heart disease?

Preclinical evidence shows CBD has anti-inflammatory and cardioprotective properties, but clinical trials in humans are still very limited. It should not replace standard cardiac medications.

What heart conditions might benefit from CBD?

Early research suggests possible benefits for recurrent pericarditis, myocarditis, ischemia-reperfusion injury, and cardiac arrhythmias, though more trials are needed.

Read More on RethinkTHC

Cite This Study

RTHC-08059·https://rethinkthc.com/research/RTHC-08059

APA

Abdalla, Hesham M; Bacon, Adam; VanDolah, Hunter; Dreher, Luke; Pathangey, Girish; Abdelnabi, Mahmoud; Ibrahim, Ramzi; Pereyra, Milagros; Farina, Juan M; Luis, S Allen; Arsanjani, Reza; Ayoub, Chadi. (2026). Cannabidiol in Cardiovascular Disease: A Review of Current Evidence and Future Directions.. Mayo Clinic proceedings, 101(2), 297-309. https://doi.org/10.1016/j.mayocp.2025.10.009

MLA

Abdalla, Hesham M, et al. "Cannabidiol in Cardiovascular Disease: A Review of Current Evidence and Future Directions.." Mayo Clinic proceedings, 2026. https://doi.org/10.1016/j.mayocp.2025.10.009

RethinkTHC

RethinkTHC Research Database. "Cannabidiol in Cardiovascular Disease: A Review of Current E..." RTHC-08059. Retrieved from https://rethinkthc.com/research/abdalla-2026-cannabidiol-in-cardiovascular-disease

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.